Diagenta will attend the AusBiotech International Conference, part of Australia’s Biggest Week in Biotech, on 21–23 October 2026 at the Gold Coast Convention & Exhibition Centre, Australia. The event connects biotech companies, researchers and investors from around the world.
Diagenta will participate in the AusBiotech International Conference on 21–23 October 2026 at the Gold Coast Convention & Exhibition Centre in Queensland, Australia. Part of Australia’s Biggest Week in Biotech, the conference brings together biotechnology companies, researchers and investors to share insights and explore partnerships. We look forward to connecting with the international life sciences community.
Rambam Holding AG continues to strengthen its end-to-end model, from preclinical discovery in Portugal to clinical sites in Uzbekistan and bioanalysis in Australia.
The group remains focused on delivering high-quality, inspection-ready research across all locations.
Navegador continues to progress target validation, biology, pharmacology and DMPK/ADME activities, supporting candidate selection for the group's pipeline.
Rambac is actively preparing and activating clinical sites, training site staff and maintaining readiness for inspections and audits.
Diagenta continues method development, validation, sample management and quality control, ensuring reliable bioanalytical support for the group's programmes.
Across all companies, Rambam Holding AG maintains shared QA/QMS, legal, IT, HR and finance functions, ensuring consistent standards and regulatory readiness.
Rambam AG, a Swiss-based venture studio and part of the Expert Systems accelerator platform, and NLC Health Ventures have announced the pre-seed funding and launch of NeurOdys Therapeutics, a biotech start-up headquartered in Amsterdam.
NeurOdys brings together scientists, drug developers and investors to discover and advance novel small molecules that aim to change the course of Alzheimer’s, Parkinson’s and other neurodegenerative disorders.
The company will use advanced computational modelling and discovery technologies to identify candidates quickly, supported by the drug development expertise of Expert Systems Accelerator, a vertically integrated, AI-powered discovery platform.
According to Dr. Vasily Kazey, CEO of NeurOdys, the backing of Rambam AG and NLC Health Ventures puts the team in a strong position to make real progress toward disease-modifying therapies.
Rambam AG has acquired Diagenta Inc., a US outpatient medical services and clinical and bioanalytical research organization with a wholly owned subsidiary in Australia.
Sanja Tomovska, Chief Growth Officer, and Rouslan Michtchenko, Executive Director, will represent Rambam AG at BIO-Europe 2024 in Stockholm, Sweden, from 4 to 6 November 2024.
BIO-Europe is Europe’s leading partnering conference for the biotech and life sciences sectors, bringing together professionals from around the world.
With a presence in both US and European markets, Rambam sees the event as a chance to build strategic partnerships. Rouslan Michtchenko noted that the team looks forward to discussing the future of drug discovery and how Rambam’s approach turns scientific insight into real-world therapies.
Rambam AG, a European venture studio and part of the Expert Systems accelerator, is growing its presence in the European biotech landscape through a strategic collaboration with Polku Therapeutics Oy, a Helsinki-based company developing treatments for neurodegenerative diseases.
The collaboration reflects Rambam’s commitment to combining biotech venture funding, rational program design and disciplined execution to translate scientific insights into novel medicines efficiently.
Dr. Ruben Abagyan spoke on giga-screening for preclinical candidates with a defined multi-target profile, looking at how first-in-class or best-in-class candidates can be identified quickly. He illustrated the topic with Eilean Therapeutics’ program for difficult targets such as FLT3 and BCL2, where rational design by the Molsoft team led to best-in-class candidates entering clinical studies in leukemias and lymphomas within two years of the program’s start.
Dr. Tudor Oprea discussed whether humans can learn from machine learning in drug discovery, highlighting the work of the Molsoft and Expert Systems design teams on a best-in-class M-Pro/3CL candidate for COVID-19 that is moving into clinical trials.